Back to Stakeholders

Enterprise Intelligence

Quarterly psychedelic drug-development briefing

Compare indication activity, programme milestones, competitive intensity, and near-term catalysts. Q2 includes quarter-over-quarter changes against the published Q1 baseline.

Browse briefingsOpen Q2 briefing

Purisys is a US active-pharmaceutical-ingredient CDMO based in Athens, Georgia, spun off from Noramco in 2019 (with controlled-substance manufacturing heritage dating to 1979). It provides custom synthesis of APIs, reference standards and controlled substances, and holds DEA licences for several psychedelic classes; it has produced GMP psilocybin and psilocin and filed an IND-enabling drug master file for psilocybin to support clinical-trial supply. Purisys is now part of the Siegfried Group.

Manufacturing Snapshot

Established CDMO / Manufacturer

Scope & Capabilities

API ProductionCDMO ServicesAnalytical / QC TestingRegulatory / CMC Support

Supply Use Cases

Clinical TrialsResearch UseCommercial / Licensed Supply

GxP / Compliance

cGMPDEA Controlled-Substance Compliance

Facilities & Access

Athens, Georgia API manufacturing and CDMO operation with controlled-substance specialization.

Manufacturing Details

Supported Substances

Psilocybin, psilocin, MDMA derivatives, LSD, DMT derivatives, ketamine, and ibogaine (as listed by company).

Regulatory Authorizations

1 authorization

United States - FDA / DEA

Active

FDA-inspected and DEA-licensed facilities

View source

Manufacturing Sources

Purisys Psychedelics API

https://purisys.com/api/psychedelics/

Quick Facts

Founded
2019
HQ
United States
Website
Visit